{"title":"Hentriacontane 对地塞米松诱导的大鼠胰岛素抵抗的作用","authors":"Arjina Sultana, Bhrigu Kumar Das , Dipankar Saha","doi":"10.1016/j.prenap.2024.100063","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>The worldwide incidence of morbidity and mortality linked to diabetes mellitus is on the ascent, with insulin resistance (IR) standing out as a key characteristic. Given the restricted safety and effectiveness observed in current therapeutic approaches, there exists a demand for novel anti-diabetic pharmaceuticals. This study aims to explore the impact of Hentriacontane, a naturally occurring long-chain alkane hydrocarbon, in an experimental model of IR induced by dexamethasone. The animals were administered dexamethasone (0.08 mg/kg b.w. <em>s.c.</em>) for six weeks to produce IR in the experimental animals. The animals distributed into five groups (n = 6) were: Normal group, IR group, IR + Hentriacontane low dose (2 mg/kg b.w./day <em>p.o.</em>), IR + Hentriacontane high dose (5 mg/kg b.w./day <em>p.o.</em>), and IR + Metformin (250 mg/kg b.w./day <em>p.o.</em>). Following the experimental period, blood/serum samples were taken for the assessment of various biochemical parameters, and a histopathological investigation of the pancreas was carried out.</p></div><div><h3>Results</h3><p>The inhibitory concentration (IC<sub>50</sub>) value of Hentriacontane in various <em>in-vitro</em> assays targeting anti-diabetic and anti-oxidant effects indicates its efficacy in mitigating diabetes and scavenging free radicals. Findings from <em>in-vivo</em> studies demonstrate that this phytoconstituent notably lowers fasting glucose, insulin, and homeostasis model assessment of insulin resistance (HOMA-IR) levels in dexamethasone-induced diabetic rats. Administration of hentriacontane effectively counteracts dexamethasone-induced impairments in oral glucose tolerance tests. Further, Hentriacontane normalizes lipid profiles and restores beta-cell function in diabetic rats.</p></div><div><h3>Conclusion</h3><p>This study has provided scientific support and evidence that Hentriacontane has a positive hypoglycemic impact on insulin-resistant rats induced by dexamethasone. Additional studies are required to ascertain the most effective dosage, duration of therapy and molecular mode of action.</p></div>","PeriodicalId":101014,"journal":{"name":"Pharmacological Research - Natural Products","volume":"4 ","pages":"Article 100063"},"PeriodicalIF":0.0000,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Role of Hentriacontane on dexamethasone-induced insulin resistance in rats\",\"authors\":\"Arjina Sultana, Bhrigu Kumar Das , Dipankar Saha\",\"doi\":\"10.1016/j.prenap.2024.100063\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>The worldwide incidence of morbidity and mortality linked to diabetes mellitus is on the ascent, with insulin resistance (IR) standing out as a key characteristic. Given the restricted safety and effectiveness observed in current therapeutic approaches, there exists a demand for novel anti-diabetic pharmaceuticals. This study aims to explore the impact of Hentriacontane, a naturally occurring long-chain alkane hydrocarbon, in an experimental model of IR induced by dexamethasone. The animals were administered dexamethasone (0.08 mg/kg b.w. <em>s.c.</em>) for six weeks to produce IR in the experimental animals. The animals distributed into five groups (n = 6) were: Normal group, IR group, IR + Hentriacontane low dose (2 mg/kg b.w./day <em>p.o.</em>), IR + Hentriacontane high dose (5 mg/kg b.w./day <em>p.o.</em>), and IR + Metformin (250 mg/kg b.w./day <em>p.o.</em>). Following the experimental period, blood/serum samples were taken for the assessment of various biochemical parameters, and a histopathological investigation of the pancreas was carried out.</p></div><div><h3>Results</h3><p>The inhibitory concentration (IC<sub>50</sub>) value of Hentriacontane in various <em>in-vitro</em> assays targeting anti-diabetic and anti-oxidant effects indicates its efficacy in mitigating diabetes and scavenging free radicals. Findings from <em>in-vivo</em> studies demonstrate that this phytoconstituent notably lowers fasting glucose, insulin, and homeostasis model assessment of insulin resistance (HOMA-IR) levels in dexamethasone-induced diabetic rats. Administration of hentriacontane effectively counteracts dexamethasone-induced impairments in oral glucose tolerance tests. Further, Hentriacontane normalizes lipid profiles and restores beta-cell function in diabetic rats.</p></div><div><h3>Conclusion</h3><p>This study has provided scientific support and evidence that Hentriacontane has a positive hypoglycemic impact on insulin-resistant rats induced by dexamethasone. Additional studies are required to ascertain the most effective dosage, duration of therapy and molecular mode of action.</p></div>\",\"PeriodicalId\":101014,\"journal\":{\"name\":\"Pharmacological Research - Natural Products\",\"volume\":\"4 \",\"pages\":\"Article 100063\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-06-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacological Research - Natural Products\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S295019972400051X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacological Research - Natural Products","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S295019972400051X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景与糖尿病相关的全球发病率和死亡率呈上升趋势，其中胰岛素抵抗（IR）是一个主要特征。鉴于目前治疗方法的安全性和有效性受到限制，人们对新型抗糖尿病药物的需求日益增长。本研究旨在探讨天然长链烷烃 Hentriacontane 对地塞米松诱导的 IR 实验模型的影响。给动物注射地塞米松（0.08 mg/kg b.w. s.c.）六周，使实验动物产生 IR。动物被分为五组（n = 6），分别是：正常组、IR 组、IR + IR 组、IR + IR 组、IR + IR 组：正常组、IR 组、IR + Hentriacontane 低剂量组（2 毫克/千克体重/天，口服）、IR + Hentriacontane 高剂量组（5 毫克/千克体重/天，口服）和 IR + 二甲双胍组（250 毫克/千克体重/天，口服）。实验结束后，采集血液/血清样本以评估各种生化指标，并对胰腺进行组织病理学检查。结果在各种以抗糖尿病和抗氧化作用为目标的体外实验中，亨特拉康坦的抑制浓度（IC50）值表明它具有缓解糖尿病和清除自由基的功效。体内研究结果表明，这种植物成分能显著降低地塞米松诱导的糖尿病大鼠的空腹血糖、胰岛素和胰岛素抵抗平衡模型评估（HOMA-IR）水平。服用亨特拉康坦可有效抵消地塞米松诱导的口服葡萄糖耐量试验损伤。结论这项研究提供了科学支持和证据，证明亨特拉康坦对地塞米松诱导的胰岛素抵抗大鼠具有积极的降血糖作用。要确定最有效的剂量、疗程和分子作用模式，还需要进行更多的研究。
Role of Hentriacontane on dexamethasone-induced insulin resistance in rats
Background
The worldwide incidence of morbidity and mortality linked to diabetes mellitus is on the ascent, with insulin resistance (IR) standing out as a key characteristic. Given the restricted safety and effectiveness observed in current therapeutic approaches, there exists a demand for novel anti-diabetic pharmaceuticals. This study aims to explore the impact of Hentriacontane, a naturally occurring long-chain alkane hydrocarbon, in an experimental model of IR induced by dexamethasone. The animals were administered dexamethasone (0.08 mg/kg b.w. s.c.) for six weeks to produce IR in the experimental animals. The animals distributed into five groups (n = 6) were: Normal group, IR group, IR + Hentriacontane low dose (2 mg/kg b.w./day p.o.), IR + Hentriacontane high dose (5 mg/kg b.w./day p.o.), and IR + Metformin (250 mg/kg b.w./day p.o.). Following the experimental period, blood/serum samples were taken for the assessment of various biochemical parameters, and a histopathological investigation of the pancreas was carried out.
Results
The inhibitory concentration (IC50) value of Hentriacontane in various in-vitro assays targeting anti-diabetic and anti-oxidant effects indicates its efficacy in mitigating diabetes and scavenging free radicals. Findings from in-vivo studies demonstrate that this phytoconstituent notably lowers fasting glucose, insulin, and homeostasis model assessment of insulin resistance (HOMA-IR) levels in dexamethasone-induced diabetic rats. Administration of hentriacontane effectively counteracts dexamethasone-induced impairments in oral glucose tolerance tests. Further, Hentriacontane normalizes lipid profiles and restores beta-cell function in diabetic rats.
Conclusion
This study has provided scientific support and evidence that Hentriacontane has a positive hypoglycemic impact on insulin-resistant rats induced by dexamethasone. Additional studies are required to ascertain the most effective dosage, duration of therapy and molecular mode of action.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
